biostudies-literatureUnknown17(1)Yan M<h4>Background</h4>Elderly patients with relapsed acute myeloid leukemia (AML) have limited treatment options and a poor prognosis. Venetoclax combined with azacitidine has shown promising activity in newly diagnosed or relapsed/refractory AML, but real-world data on older populations remain scarce. This study aimed to evaluate the efficacy, safety, and prognostic factors - including select blood biomarkers - of venetoclax plus azacitidine in elderly patients with relapsed AML.<h4>Methods</h4>We conducted a single-center retrospective review of patients aged ≥65 years diagnosed with relapsed AML who received venetoclax plus azacitidine between January 2018 and December 2022. Patient demographics, baseline disease characteristics, and treatment details were collected. Blood biomarkers, suchMediterranean journal of hematology and infectious diseasese2025058https://www.ebi.ac.uk/biostudies/studies/S-EPMC12422247biostudies-literatureEfficacy of Venetoclax Combined with Azacitidine in Elderly Patients with Relapsed Acute Myeloid Leukemia.PMC12422247Yan MXu LWang GWang JfalseEfficacy of Venetoclax Combined with Azacitidine in Elderly Patients with Relapsed Acute Myeloid Leukemia.<h4>Background</h4>Elderly patients with relapsed acute myeloid leukemia (AML) have limited treatment options and a poor prognosis. Venetoclax combined with azacitidine has shown promising activity in newly diagnosed or relapsed/refractory AML, but real-world data on older populations remain scarce. This study aimed to evaluate the efficacy, safety, and prognostic factors - including select blood biomarkers - of venetoclax plus azacitidine in elderly patients with relapsed AML.<h4>Methods</h4>We conducted a single-center retrospective review of patients aged ≥65 years diagnosed with relapsed AML who received venetoclax plus azacitidine between January 2018 and December 2022. Patient demographics, baseline disease characteristics, and treatment details were collected. Blood biomarkers, such2025-01-01T00:00:00Z20252026-06-02T20:28:15.038Z2026-04-20T03:09:59.416ZS-EPMC124222474093731110.4084/MJHID.2025.058